Trial document




This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00003787

Trial Description

start of 1:1-Block title

Title

Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Doxo

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the
predictive role of troponin and natriuretic peptides for anthracycline-induced
cardiotoxicity .

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

- Paediatric patients up to the age of 17 years will be included. Number and time points
of PK sampling will depend on age and tumour type.

- PK samples will be collected from two doxorubicin administrations. Analyzing samples
from two doxorubicin administrations will allow distinguishing between interindividual,
intraindividual and residual variability.

- Doxorubicin and its major metabolite doxorubicinol will be measured in plasma using
HPLC

- In addition, the natriuretic peptide BNP and the precursors NT-pro ANP and NT-proBNP as
well as troponin T will be measured in plasma up to 28 days after doxorubicin
administration to evaluate their use as clinical markers for cardiotoxicity.

- A data set of max 5 samples (3 +2 (in the 1st + 2nd Doxorubicin sampling periods)) will
be collected in the younger children (< 3 years) and a data set of max. 8 samples ( 5 +
3) will be collected in the older children. Samples will be taken at predefined time
points/ time intervals.

- An additional DNA sample will be taken and analyzed for genetic polymorphisms. The
influence of genotype on pharmacokinetics and metabolism will be investigated by
appropriate statistical methods, including population pharmacokinetic analyses. Genes
to study would include MDR1 and SLC22A16, both involved in the transport of doxorubicin
and AKR1A1 and CBR1, both involved in the reduction of doxorubicin to doxorubicinol.
Selected genotypes will be incorporated as covariates into the population
pharmacokinetic models developed. The potential impact of genetic variation will be
evaluated in the context of other sources of variability such as age, weight, gender
etc

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003787
  •   2012/05/04
  •   2010/03/22
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2009-011454-17 
  •   NCT01095926  (ClinicalTrials.gov)
  •   EPOC-MS-001  (University Hospital Muenster)
  •   2009-011454-17 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Wilms Tumor
  •   Neuroblastoma
  •   Soft Tissue Sarcoma
  •   Acute Lymphoblastic Leukemia
  •   C91.0 -  Acute lymphoblastic leukaemia
  •   C64 -  Malignant neoplasm of kidney, except renal pelvis
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: doxorubicin
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Assess age-dependency in pharmacokinetics of doxorubicin in paediatric patients with solid tumours and leukaemia; time frame: 24h; Measure doxorubicin and doxorubicinol concentration in blood plasma. Collect samples at two different doxorubicin infusions.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Assess interindividual, intraindividual and residual variability of PK parameters in children; time frame: 24h; Measure doxorubicin and doxorubicinol concentration in blood plasma. Collect samples at two different doxorubicin infusions.
- Assess relationship between PK parameters and patient characteristics; time frame: 24h; Measure doxorubicin and doxorubicinol concentration in blood plasma. Collect samples at two different doxorubicin infusions.
- Explore in a preliminary fashion genetic polymorphisms that may influence doxorubicin clearance; time frame: 5 years; Obtain one whole blood sample per patient, if separate consent was given.
- Evaluate the potential role of natriuretic peptides and troponin as indicators for subclinical cardiotoxicity; time frame: 1 month; Measure troponin T, troponin I, BNP, NT-proBNP, NT-proANP. Collect samples at two different doxorubicin infusions before and up to 1month after doxorubicin administration.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   France
  •   Germany
  •   Italy
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2010/05/31
  •   100
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   17   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- patients ≤ 17 years of age

- plan to receive at least two cycles of doxorubicin

- must be enrolled in a national or European protocol for treatment of Wilms Tumours,
Neuroblastoma, Soft tissue sarcoma, Ewing Sarcoma or Acute lymphoblastic leukaemia
and must be treated with doxorubicin according to that protocol Or Patients < 3 years
enrolled or listed in any national or European study protocol for any paediatric
malignancy. Treatment with doxorubicin has to be according to that protocol.

- Parents or legal representative(s) must provide written informed consent to
participate in the trial according to national regulations. Patients that are able to
understand should provide assent to participate in the trial.

- Life expectancy of at least 3 month

- Karnofsky performance status of ≥ 70%

- Additional blood withdrawal is acceptable for the patient. The decision is left to
the investigator

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- prior cardiac problems

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • University Hospital Muenster
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • University Hospital Muenster
    • Joachim Boos, MD, Prof. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • University Hospital Muenster
    • Joachim Boos, MD, Prof. 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2013/05/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   53
  •   2013/10/30
* This entry means the parameter is not applicable or has not been set.